Finance

03/17/23

Woah! Are Phase 3s no longer enough for CMS?

Biotech

Finance

03/12/23

Act now to prevent SVB’s failure from becoming a national crisis

Biotech

Finance

Policy

Planetary

03/10/23

A crisis we don’t need: How not to cause a bank run

Biotech

Finance

02/09/23

FutureCast | Time to Reboot Biotech

Biotech

Finance

01/03/23

Semper Maior: Time to Reboot Biotech

Biotech

Finance

12/21/22

What you were reading — RApport’s 2022 Top Ten

Culture

Finance

Policy

Science

12/20/22

We shut down our SPAC — here’s why

Finance

11/22/22

I walked 100 miles for this term sheet

Biotech

Culture

Finance

11/16/22

Transforming Forma — The Science of Giving a Damn

Biotech

Culture

Finance

10/31/22

Alnylam is doing what the IRA is telling it to do

Biotech

Finance

Policy

09/21/22

Saving money for Medicare by abandoning new drugs for Medicare patients

Biotech

Finance

Policy

05/31/22

Biotech’s Dulcius Ex Asperis: The Way Through This Downturn (Bionic Reading)

Finance

05/27/22

Biotech’s Dulcius Ex Asperis: The Way Through This Downturn

Biotech

Finance

05/25/22

Step-by-step price discovery for private companies

Finance

04/08/22

Do stocks trading near cash offer free upside?

Biotech

Finance

04/06/22

Matchmaking for proteins: Introducing TRIANA Biomedicines

Biotech

Finance

02/08/22

A new, data-driven way to build a biotech board

Finance

01/27/22

Addressing the elephant in the boardroom

Finance

11/12/21

Practical considerations for conducting a Series I IPO

Biotech

Finance

10/19/21

Vaccines and the inverted capital dilemma

Biotech

Culture

Finance

Science